MIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a I…

Advancing toward Phase 2a clinical evaluation in chemotherapy-related pain, a condition with no approved treatments and ...